Expertise in
1
conditions

Yann Izarzugaza

Madrid, MD, ES 
Expertise in
1
conditions
Madrid, MD, ES 

Overview

Yann Izarzugaza practices practicing medicine in Madrid, Spain.

Mr. Izarzugaza is highly rated in 1 condition, according to our data. His clinical expertise encompasses Breast Cancer, EGFR Positive Lung Cancer, Lung Cancer, and Triple-Negative Breast Cancer.

He is actively involved in clinical research, co-authoring 10 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Madrid, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drug: Spartalizumab
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 1 Less Clinical Trial

10 Total Publications

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.
Journal: ESMO open
Published: June 16, 2025

Frequently Asked Questions about Yann Izarzugaza

Is Yann Izarzugaza a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Yann Izarzugaza is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yann Izarzugaza participate in research or clinical trials?

Yes. Yann Izarzugaza has published 10 articles and abstracts on conditions like Breast Cancer. You can view a list of Yann Izarzugaza's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Izarzugaza's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile